Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

2023283 citationsJournal Articlehybrid Open Access

Authors

Shannon N. Westin · The University of Texas MD Anderson Cancer Center

Kathleen N. Moore · University of Oklahoma Medical Center

Hye Sook Chon · Moffitt Cancer Center

Jung‐Yun Lee · Yonsei University

Jessica Thomes Pepin · Minnesota Oncology

Michael Sundborg · FirstHealth of the Carolinas

Ayelet Shai ·

Abstract

Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer.

Topics & Keywords

PARP inhibition in cancer therapy Genetic factors in colorectal cancer Ovarian cancer diagnosis and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 42, Issue 3, pp. 283-299

DOI: 10.1200/jco.23.02132

Field-Weighted Citation Impact: 65.02